Last reviewed · How we verify

NCT03106402

Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification

Completed Last updated 10 April 2017
What this trial tests

trial testing topical bromfenac sodium hydrate in Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification in 316 participants. Completed in 30 July 2015.

Timeline
1 October 2013
Primary endpoint
30 June 2015
30 July 2015

Quick facts

Lead sponsorKyungpook National University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment316
Start date1 October 2013
Primary completion30 June 2015
Estimated completion30 July 2015

Drugs / interventions tested

Conditions studied

Sponsor

Kyungpook National University Hospital

Who can join

Eligibility, any sex, with Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the incidence, risk factors and clinical courses of cystic macular lesions (CMLs) after uncomplicated phacoemulsification and evaluate the efficacy of topical NSAIDs on the prevention of pseudophakic cystic macular lesions

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Kyungpook National University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03106402.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing